The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Portfolio Pulse from Benzinga Insights
Six analysts have recently evaluated Roivant Sciences (NASDAQ:ROIV), with all ratings being bullish. The average 12-month price target has increased to $18.33 from $16.25. Analysts have maintained or raised their price targets, reflecting positive sentiment towards the company's financial performance, including significant revenue growth and strong profitability metrics.
May 31, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown a bullish sentiment towards Roivant Sciences, with an increased average price target of $18.33. The company's strong financial performance, including significant revenue growth and high profitability metrics, supports this positive outlook.
All six analysts have given bullish ratings, with some raising their price targets. The company's strong financial metrics, including a 117.8% revenue growth rate, high net margin, ROE, and ROA, contribute to the positive sentiment. The increased average price target from $16.25 to $18.33 further indicates confidence in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100